Price (delayed)
$5.72
Market cap
$349.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.57
Enterprise value
$259.23M
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing
There are no recent dividends present for SAGE.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.